Figure 4.
(A) PFS and (B) OS in patients with SCLC treated with immunotherapy in the irAEs and no-irAEs cohorts. irAE, immune-related adverse event; OS, overall survival; PFS, progression-free survival.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.